Comparative Pharmacology
Head-to-head clinical analysis: GRISACTIN versus GRISEOFULVIN ULTRAMICROSIZE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GRISACTIN versus GRISEOFULVIN ULTRAMICROSIZE.
GRISACTIN vs GRISEOFULVIN, ULTRAMICROSIZE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to microtubules and disrupts mitotic spindle formation, inhibiting fungal cell division.
Binds to tubulin, disrupting microtubule function and inhibiting fungal cell mitosis; deposited in keratin precursor cells, making keratin resistant to fungal invasion.
500 mg orally once daily or 250 mg orally twice daily for dermatophyte infections.
250-375 mg orally once daily or 500-750 mg orally once daily for severe infections.
None Documented
None Documented
Terminal elimination half-life: 9–24 hours (mean ~14 hours). Clinical context: Steady-state achieved in 3–5 days; once-daily dosing is effective due to prolonged half-life.
9-24 hours (mean 15 hours); prolonged in liver disease.
Renal: <1% as intact drug; fecal: >99% as metabolites (mainly 6-demethylgriseofulvin glucuronide) via bile; negligible biliary excretion of parent compound.
Renal (<1% unchanged); fecal (36% as metabolites); tissue deposition may persist for weeks.
Category C
Category D/X
Antifungal
Antifungal